This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mackie, G. C. Articles by Schteingart, D. E. Search for Related Content PubMed PubMed Citation Articles by Mackie, G. C. Articles by Schteingart, D. E. Related Collections Adrenal and Hypertension Endocrine Oncology

Use of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography in Evaluating Locally Recurrent and Metastatic Adrenocortical Carcinoma

Department of Radiology, Division of Nuclear Medicine (G.C.M., B.L.S.); Department of Internal Medicine, Divisions of Hematology-Oncology (F.P.W.) and Endocrinology and Metabolism (D.E.S.); Department of Surgery (P.G.G.); and Department of Pediatrics and Communicable Diseases (R.J.M.), University of Michigan Medical Center, Ann Arbor, Michigan 48109; Departments of Radiological Sciences (B.L.S.) and Hematology-Oncology (R.C.R., C.R.-G.), St. Jude Children’s Research Hospital, Memphis, Tennessee 38105; Department of Radiology (L.P.C.), Children’s Hospital, Boston, Massachusetts 02115; Department of Pediatrics (C.A.H.), Maine Medical Center, Portland, Maine 04074; and Departments of Pediatrics (G.K.) and Radiology (J.W.W.), Washington University School of Medicine, St. Louis, Missouri 63110

Address all correspondence and requests for reprints to: Barry L. Shulkin, M.D., Department of Radiological Sciences, St. Jude Children’s Research Hospital, 332 North Lauderdale, Mail Stop 752, Memphis, Tennessee 38105-2794. E-mail: Barry.shulkin{at}stjude.org.

Context: Adrenocortical carcinomas are uncommon, and their evaluation by [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG PET) has not been well evaluated.

Objective: The purpose of this study was to examine the potential utility of FDG PET in the detection of recurrent or metastatic adrenocortical carcinoma.

Design: In patients with known adrenocortical carcinoma who underwent FDG-PET imaging for suspected recurrence or metastasis, FDG activity was compared with other imaging findings, clinical features, and the presence or absence of disease as confirmed by resection, biopsy, or clinical follow-up.

Setting: The study took place at four tertiary referral centers.

Patients or Other Participants: Twelve patients (10 females and two males, 5–71 yr of age) were evaluated.

Main Outcome Measures: The main outcome measures were FDG activity, other imaging findings, and clinical features.

Results: Abnormal FDG uptake correctly indicated tumor recurrence in 10 patients. One patient with no abnormal FDG activity had a morphological abnormality subsequently proven to be a postoperative scar. Two patients, one with very small pulmonary lesions and one with a hepatic metastasis, had false-negative findings.

Conclusions: Most adrenocortical carcinomas accumulate and retain FDG and thus can be visualized by PET. However, false-negative findings are possible, especially with very small lesions.

This article has been cited by other articles:

				L. Groussin, G. Bonardel, S. Silvera, F. Tissier, J. Coste, G. Abiven, R. Libe, M. Bienvenu, J.-L. Alberini, S. Salenave, et al. 18F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Adrenocortical Tumors: A Prospective Study in 77 Operated Patients J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1713 - 1722. [Abstract] [Full Text] [PDF]

				J. F. Faria, S. M. Goldman, J. Szejnfeld, H. Melo, C. Kater, P. Kenney, M. P. Huayllas, G. Demarchi, V. V. Francisco, C. Andreoni, et al. Adrenal Masses: Characterization with in Vivo Proton MR Spectroscopy Initial Experience Radiology, December 1, 2007; 245(3): 788 - 797. [Abstract] [Full Text] [PDF]